Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

Chimeric antigen receptor T (CAR-T) cell therapy has been a milestone breakthrough in the treatment of hematological malignancies, offering an effective therapeutic option for multi-line therapy-refractory patients. So far, abundant CAR-T products have been approved by the United States Food and Dru...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shu Zhou, Yuhang Yang, Yulu Jing, Xiaoying Zhu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-09-01
coleção:	Frontiers in Immunology
Assuntos:	chimeric antigen receptor T cell hematological malignancies targets allogeneic combinatorial therapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1435635/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!